Intas and Henlius receive positive CHMP opinion for HETRONIFLY® (HANSIZHUANG in China) as first-line treatment for extensive-stage small cell lung cancer
Sep 25, 2024
Ahmedabad (Gujarat) [India], September 25: Intas Pharmaceuticals Limited ("Intas") has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of HETRONIFLY® (serplulimab, approved as HANSIZHUANG in China), in European markets.
Read More ..